YBGJOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

Yubo International Biotech Ltd

Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.01+0.00 (0.00%)

Close on Oct 16, 2026

Market cap: $886.19K
P/E (TTM): –
Dividend yield: –

Yubo International Biotech Ltd income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2025-12-31	FY 2025 2024-12-31	FY 2024 2023-12-31	FY 2023 2022-12-31	FY 2022 2021-12-31	FY 2020 2020-02-29	FY 2019 2019-02-28	FY 2018 2018-02-28	FY 2017 2017-02-28	FY 2016 2016-02-29	FY 2015 2015-02-28	FY 2014 2014-02-28	FY 2013 2013-02-28	FY 2012 2012-02-29	FY 2011 2011-02-28
Revenue	0.01	0.00	0.60	0.10	1.24	0	0	0	0	0	0	0	–	0	0
Cost of Revenue	0.00	0.00	0.19	0.05	0.42	–	–	–	–	–	–	–	–	–	–
Gross Profit	0.01	0.00	0.42	0.05	0.82	–	–	–	–	–	–	–	–	–	–
Selling, General & Admin	–	–	–	–	–	0.03	0.05	0.06	0.15	0.06	0.06	0.06	0.06	0.05	0.08
Operating Expenses	1.20	1.77	1.61	1.26	2.36	–	–	–	–	–	–	–	–	–	–
Operating Income	-1.19	-1.77	-1.19	-1.21	-1.54	-0.03	-0.05	-0.06	-0.15	-0.06	-0.06	-0.06	-0.06	-0.05	-0.08
Interest Expense	–	–	–	–	–	0.11	0.10	0.09	0.08	0.07	0.06	0.05	0.04	0.04	0.03
Other Non-Operating Income	0.00	-0.21	0.00	0.00	0.00	-0.11	-0.10	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	0.11	–	–	–	–	–	–
Legal Settlements	–	–	–	–	–	0	0	–	–	–	–	–	–	–	–
Pretax Income	-1.19	-1.98	-1.20	-1.20	-1.54	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	0	0	0	0	0	0	0	0	0	0	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-1.19	-1.98	-1.20	-1.20	1.54	–	-0.15	-0.14	-0.22	-0.13	-0.12	-0.11	-0.10	-0.08	-0.11
Minority Interest in Earnings	-0.11	-0.21	0	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-1.08	-1.78	-1.20	-1.20	-1.54	-0.13	-0.15	-0.14	-0.22	-0.13	-0.12	-0.11	-0.10	-0.08	-0.11
Net Income to Common	-1.08	-1.78	-1.20	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	–	–	–	–	–	-0.11	-0.13	-0.12	-0.19	-0.11	-0.10	-0.09	-0.09	-0.07	-0.09
EPS (Diluted)(per share)	-0.01	-0.02	-0.10	–	–	-0.11	-0.13	-0.12	-0.19	-0.11	-0.10	-0.09	-0.09	-0.07	-0.09
Shares Outstanding (Basic, Weighted)(shares)	–	–	–	–	–	1.18	1.18	1.18	1.18	1.18	1.18	1.18	1.18	1.18	–
Shares Outstanding (Diluted, Weighted)(shares)	140	120	12	–	–	1.18	1.18	1.18	1.18	1.18	1.18	1.18	1.18	1.18	–
EBITDA	-1.02	-1.60	-1.02	-1.19	-1.53	–	–	–	–	–	–	–	–	–	–
Net Interest Income	–	0.00	0.00	0.00	0.00	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 66.1%
Operating margin: -9096.9%
Net margin: -8157.3%
Return on equity, FY2026: 40.1%

Financial strength

Current ratio: 0.18
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.4%

Valuation

P/E ratio: –
Price to sales: 71.74
Price to book: –
Dividend yield: –